GSK Bio's influenza vaccine GSK2186877A

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Influenza

Phase 3

Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older

CompletedNCT00753272

GlaxoSmithKlineInfluenza

Start: 2008-09-15End: 2011-01-05Updated: 2018-06-08

Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older

CompletedNCT00760617

GlaxoSmithKlineInfluenza

Start: 2008-10-06End: 2009-05-15Updated: 2018-08-17

Related Papers

Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and <i>post-hoc</i> correlate of protection analysis

Human Vaccines & Immunotherapeutics2016-10-0310 citations

Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines.

2014-04-0424 citations

Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial.

2013-07-2630 citations

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.

2013-03-19120 citations